Relapse of Alopecia Areata Responders After Tofacitinib Withdrawal: A Retrospective Study of 59 Patients

Abstract

Keywords

alopecia areata tofacitinib relapse JAK inhibitor re-treatment

Get full access to this article

View all access options for this article.

References

Rudnicka

Arenbergerova

Grimalt

, et al European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687-694. doi:10.1111/jdv.19768

Huang

Deng

, et al Drug survival and long-term outcome of tofacitinib in patients with alopecia areata: a retrospective study. Acta Derm Venereol. 2023;103:adv13475. doi:10.2340/actadv.v103.13475

Olsen

Roberts

Sperling

, et al Objective outcome measures: Collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470-478.e473. doi:10.1016/j.jaad.2017.10.048

Wyrwich

Kitchen

Knight

, et al Development of the scalp hair assessment PRO™ measure for alopecia areata. Br J Dermatol. 2020;183(6):1065-1072. doi:10.1111/bjd.19024

Klein

Flanagan

KL.

Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-638. doi:10.1038/nri.2016.90

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB

0.02 MB

0.04 MB